Crescita Therapeutics Announces the Results of its Annual General and Special Meeting of Shareholders

LAVAL, Quebec--(BUSINESS WIRE)--Crescita Therapeutics Inc. (TSX: CTX and OTC US: CRRTF) (“Crescita” or the “Company”), a growth-oriented, innovation-driven Canadian commercial dermatology company, today announced the voting results from its Annual General and Special Meeting of Shareholders held at its corporate headquarters in Laval, Quebec on June 4, 2025. The detailed results of the votes received by proxy are as follows:

Election of Directors

Director Nominees	NUMBER OF SHARES		PERCENTAGE OF VOTES CAST
	FOR	WITHHELD	FOR	WITHHELD
Daniel N. Chicoine	5,432,232	301,172	94.75%	5.25%
Anthony E. Dobranowski	5,455,219	278,185	95.15%	4.85%
John C. London	5,427,266	306,138	94.66%	5.34%
Deborah Shannon-Trudeau	5,463,225	270,179	95.29%	4.71%
Serge Verreault	5,490,982	242,422	95.77%	4.23%

Reappointment of External Auditors

Outcome	NUMBER OF SHARES		PERCENTAGE OF VOTES CAST
	FOR	WITHHELD	FOR	WITHHELD
Ernst & Young LLP reappointed	6,388,758	49,767	99.23%	0.77%

Approval of the Continuation of Crescita’s Shareholder Rights Plan

Outcome	NUMBER OF SHARES		PERCENTAGE OF VOTES CAST
	FOR	AGAINST	FOR	AGAINST
Shareholder Rights Plan approved	5,481,368	252,036	95.60%	4.40%

About Crescita Therapeutics Inc.
Crescita (TSX: CTX and OTC US: CRRTF) is a growth-oriented, innovation-driven Canadian commercial dermatology company with in-house R&D and manufacturing capabilities. The Company offers a portfolio of high-quality, science-based non-prescription skincare products and a commercial stage prescription product. We also own multiple proprietary transdermal delivery platforms that support the development of patented formulations to facilitate the delivery of active ingredients into or through the skin. For more information visit, www.crescitatherapeutics.com.

Source: Crescita Therapeutics